News | June 22, 2022
AstraZeneca and Merck announces results from phase 3 PROpel trial of Lynparza
LYNPARZA is approved in the U.S. for patients with HRR gene-mutated mCRPC (BRCA-mutated and other HRR gene mutations)
LYNPARZA is approved in the U.S. for patients with HRR gene-mutated mCRPC (BRCA-mutated and other HRR gene mutations)
It is only the second healthcare provider in the world to attain the Stage 6 DIAM certification.
Indira IVF has established technological supremacy as the key differentiator, delivering industry leading success rate
TRIPS waiver for five years agreed in the recently concluded WTO will help countries manufacture COVID vaccines to deal with the pandemic
With $120m jointly invested in the newly-formed initiative, and with other strategic investors expected to join, the venture will develop an alternative, plant-based ingredient using biotechnology
The company has a total sales of Rs. 25.8 crore during FY 21-22 and Rs. 26.4 crore during FY 20-21.
Both manufacturing facilities are based out of Benguluru, India
Ganguly will execute company's strategic focus on leveraging CustomGlycan to develop novel therapeutics
The capacity addition in Suwa is part of Saint-Gobain Life Sciences ongoing investment plan to globally expand production capacity for its products and services used throughout the bioprocessing industry
EPR-Technologies is pursuing development of an unprecedented standard of emergency care when CPR fails
Subscribe To Our Newsletter & Stay Updated
